Results of all-cause mortality following hospitalisation for pneumonia: a subanalysis of patients with rheumatoid arthritis (RA) and their preadmission treatments for RA with patients receiving methotrexate as a reference
| RA therapy | Mortality at 30 days n (%) | HRs 30-day mortality | Mortality at 90 days n (%) | HRs 90-day mortality | |||
| N | Crude | Adjusted* | Crude | Adjusted* | |||
| All | 1220 | 165 (13.5) | 243 (19.9) | ||||
| Methotrexate monotherapy | 143 | 16 (11.2) | 1.0 (ref) | 1.0 (ref) | 23 (16.1) | 1.0 (ref) | 1.0 (ref) |
| Any prednisolone† | 526 | 71 (13.5) | 1.23 (0.72 to 2.12) | 1.16 (0.68 to 2.01) | 121 (23.0) | 1.48 (0.95 to 2.31) | 1.43 (0.91 to 2.22) |
| Any biologics | 46 | 1 (2.2) | 0.19 (0.02 to 1.42) | 0.35 (0.05 to 2.66) | 1 (2.2) | 0.13 (0.02 to 0.94) | 0.21 (0.03 to 1.56) |
| Other csDMARDS as monotherapy | 63 | 8 (12.7) | 1.17 (0.50 to 2.73) | 1.24 (0.53 to 2.92) | 10 (15.9) | 1.01 (0.48 to 2.12) | 1.09 (0.52 to 2.29) |
| Combination therapy (csDMARDs) | 48 | 1 (2.0) | 0.18 (0.02 to 1.34) | 0.27 (0.36 to 2.06) | 3 (6.2) | 0.37 (0.11 to 1.22) | 0.56 (0.17 to 1.87) |
| No RA medication | 394 | 68 (17.3) | 1.60 (0.93 to 2.76) | 1.49 (0.86 to 2.57) | 85 (21.6) | 1.40 (0.89 to 2.23) | 1.35 (0.85 to 2.14) |
Patients categorised according to therapy registered within 1 year prior to pneumonia admission.
Each patient was assigned to one group using the hierarchy described in the text and shown in online supplementary figure 1.
*Adjusted for sex, age, level of comorbidity, alcoholism, and antibiotic use before admission.
†Prescriptions for prednisolone 0–3 months prior to admission.
csDMARDs, conventional synthetic disease-modifying antirheumatic drugs.